Recipharm AB publishes its interim report January-March 2019
January – March 2019 · Continued strong sales growth · Net sales amounted to SEK 1,812 million (1,513), an increase of 20% · EBITDA increased by 17% and amounted to SEK 291 million (250) corresponding to an EBITDA margin of 16.1% (16.5) · Strong development of newly acquired operations in UK · Operating profit (EBIT) amounted to SEK 111 million (120) · Profit after tax amounted to SEK 79 million (45) corresponding to a net margin of 4.4% (3.0) · Earnings per share amounted to SEK 1.17 (0.70) before dilution and SEK 1.17 (0.70) after dilution · Net debt to Equity